[go: up one dir, main page]

MX2009005026A - Anticuerpos anti-tsg101 y sus usos para tratamiento de infecciones virales. - Google Patents

Anticuerpos anti-tsg101 y sus usos para tratamiento de infecciones virales.

Info

Publication number
MX2009005026A
MX2009005026A MX2009005026A MX2009005026A MX2009005026A MX 2009005026 A MX2009005026 A MX 2009005026A MX 2009005026 A MX2009005026 A MX 2009005026A MX 2009005026 A MX2009005026 A MX 2009005026A MX 2009005026 A MX2009005026 A MX 2009005026A
Authority
MX
Mexico
Prior art keywords
treatment
viral infections
tsg101
antibodies
tsg101 antibodies
Prior art date
Application number
MX2009005026A
Other languages
English (en)
Inventor
Roxanne Duan
Limin Li
Michael Kinch
Michael Goldblatt
Original Assignee
Functional Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Functional Genetics Inc filed Critical Functional Genetics Inc
Publication of MX2009005026A publication Critical patent/MX2009005026A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona anticuerpos que se unen a la región C-terminal de TSG101. La invención también proporciona métodos para usar los anticuerpos de TSG101 para el tratamiento de infecciones virales, incluyendo infección de VIH y virus de ébola.
MX2009005026A 2006-11-15 2007-11-15 Anticuerpos anti-tsg101 y sus usos para tratamiento de infecciones virales. MX2009005026A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85892206P 2006-11-15 2006-11-15
PCT/US2007/084808 WO2008064072A2 (en) 2006-11-15 2007-11-15 Anti-tsg101 antibodies and their uses for treatment of viral infections

Publications (1)

Publication Number Publication Date
MX2009005026A true MX2009005026A (es) 2009-07-31

Family

ID=39430501

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005026A MX2009005026A (es) 2006-11-15 2007-11-15 Anticuerpos anti-tsg101 y sus usos para tratamiento de infecciones virales.

Country Status (11)

Country Link
US (2) US7964708B2 (es)
EP (2) EP2094282A4 (es)
JP (2) JP2010510235A (es)
CN (1) CN101641106A (es)
AU (1) AU2007323799B2 (es)
CA (1) CA2669095A1 (es)
IL (1) IL198598A0 (es)
MX (1) MX2009005026A (es)
NZ (1) NZ576878A (es)
WO (1) WO2008064072A2 (es)
ZA (1) ZA200904068B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2360182A1 (en) * 2006-11-13 2011-08-24 Functional Genetics, Inc. Therapeutic targeting of escort proteins
US20110206695A1 (en) * 2010-01-25 2011-08-25 Functional Genetics, Inc. Antibodies for diagnosis and therapeutic treatment of prostate cancer
US11918728B2 (en) 2014-04-17 2024-03-05 ImMutriX Therapeutics, Inc. Therapeutic compositions for viral-associated disease states and methods of making and using same
US9669151B2 (en) 2014-04-17 2017-06-06 ImMutriX Therapeutics, Inc. Therapeutic compositions for viral-associated disease states and methods of making and using same
US12059413B2 (en) 2016-11-02 2024-08-13 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction
CN112630449B (zh) * 2020-12-30 2022-10-18 广西壮族自治区水牛研究所 对水牛出生时间进行判断的血液外泌体标志物及其应用
GB202203066D0 (en) * 2022-03-04 2022-04-20 Univ Swansea Anti-rage antibody

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992006180A1 (en) 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
WO1992015677A1 (en) 1991-03-01 1992-09-17 Protein Engineering Corporation Process for the development of binding mini-proteins
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
JPH06510524A (ja) 1991-05-14 1994-11-24 ユニバーシティ オブ コネチカット 免疫原性タンパク質をコードする遺伝子の標的への配達
CA2103371C (en) 1991-06-05 2003-09-16 George Y. Wu Targeted delivery of genes encoding secretory proteins
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
EP0633943A4 (en) 1992-04-03 1997-05-02 Alexander T Young GENTHERAPY USING TARGETED VIRAL VECTORS.
WO1994008598A1 (en) 1992-10-09 1994-04-28 Advanced Tissue Sciences, Inc. Liver reserve cells
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
WO1997018333A1 (en) * 1995-11-16 1997-05-22 The Board Of Trustees Of The Leland Stanford Junior University Disruption of expression of multiple alleles of mammalian genes
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US20020177207A1 (en) * 2001-03-14 2002-11-28 Myriad Genetics, Incorporated Tsg101-interacting proteins and use thereof
DE60232785D1 (de) * 2001-03-14 2009-08-13 Myriad Genetics Inc Tsg101-gag-wechselwirkung und ihre verwendung
US7335468B2 (en) * 2001-03-14 2008-02-26 Myriad Genetics, Inc. TSG101-GAG interaction and use thereof
WO2002094314A1 (en) * 2001-05-21 2002-11-28 The Research Foundation Of The State University Of New York Tsg101 as inhibitor of hiv production
JP4931347B2 (ja) * 2002-10-01 2012-05-16 ファンクショナル・ジェネティクス・インコーポレイテッド 抗−ｔｓｇ１０１抗体およびウイルス感染の処置に対するそれらの用法
WO2004071462A2 (en) * 2003-02-12 2004-08-26 Johns Hopkins University Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction

Also Published As

Publication number Publication date
AU2007323799B2 (en) 2013-07-18
US20090186041A1 (en) 2009-07-23
WO2008064072A2 (en) 2008-05-29
US8796423B2 (en) 2014-08-05
EP2514439A1 (en) 2012-10-24
JP2013227331A (ja) 2013-11-07
ZA200904068B (en) 2012-09-29
CN101641106A (zh) 2010-02-03
EP2094282A2 (en) 2009-09-02
US20080187528A1 (en) 2008-08-07
IL198598A0 (en) 2010-02-17
AU2007323799A1 (en) 2008-05-29
NZ576878A (en) 2011-10-28
WO2008064072A3 (en) 2008-10-16
EP2094282A4 (en) 2010-05-05
CA2669095A1 (en) 2008-05-29
US7964708B2 (en) 2011-06-21
JP2010510235A (ja) 2010-04-02

Similar Documents

Publication Publication Date Title
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
WO2011071574A3 (en) Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
WO2010047830A3 (en) Agents for hcv treatment
PH12013501683A1 (en) Yeast-based therapeutic for chronic hepatitis b infection
EA201390538A1 (ru) Противовирусные соединения
IN2012DN01328A (es)
WO2008115281A3 (en) Compounds for treating viral infections
PH12016500859A1 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
SG10201407640PA (en) Hepatitis b virus specific antibody and uses thereof
EA032929B1 (ru) Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
WO2008127364A3 (en) Antiviral compounds and use thereof
MX2009005026A (es) Anticuerpos anti-tsg101 y sus usos para tratamiento de infecciones virales.
EA200900298A1 (ru) Ингибиторы вируса гепатита с
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
EA201390806A1 (ru) Конструкция пептидного каркаса
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
AU2012249274A8 (en) Neutralizing antibodies to Nipah and Hendra virus
EA200970586A1 (ru) Антитела к цитомегаловирусу человека (hcmv)
WO2009067191A3 (en) Methods and compositions for the treatment of hepatitis c virus (hcv) infection
EA200901080A1 (ru) Новые нуклеозидные аналоги для лечения вирусных инфекций
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
MX354676B (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv).
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
EA201170605A1 (ru) Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights